CV risk lower with metformin in T2DM and reduced kidney function
(HealthDay)—Treatment with metformin versus sulfonylureas is associated with a reduced risk for major adverse cardiovascular events (MACE) among patients with type 2 diabetes and reduced kidney function, according to a ...
Sep 19, 2019
0
2